LUMINA IgAN: A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy (clinicaltrials.gov) - Oct 1, 2026 - P3 | N=340 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals
New P3 trial • Glomerulonephritis • IgA Nephropathy • Renal Disease
|